ABHD6 inhibition rescues a sex-dependent deficit in motor coordination in the HdhQ200/200 mouse model of Huntington's disease

Jessica K. Cao

University of Washington

Katie Viray

University of Washington

Myungsun Shin

University of Virginia

Ku-Lung Hsu

University of Virginia

Ken Mackie

Indiana University Bloomington

Ruth Westenbroek

University of Washington

Nephi Stella (✉ nstella@uw.edu)

University of Washington

Research Article

Keywords: Huntington's Disease, ABHD6 inhibition

Posted Date: February 24th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-230223/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

**ABHD6 inhibition rescues a sex-dependent deficit in motor coordination
in the HdhQ200/200 mouse model of Huntington's disease**

Jessica K. Cao¹, Katie Viray¹, Myungsun Shin², Ku-Lung Hsu², Ken Mackie³, Ruth Westenbroek¹
and Nephi Stella^{1,4*}

¹Department of Pharmacology, University of Washington School of Medicine, Seattle, WA 98195, USA.

²Department of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.

³Department of Psychological and Brain Sciences, Linda and Jack Gill Center for Biomolecular Science, Indiana University, Bloomington, IN 47405, USA.

⁴Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA.

*Author for Correspondence:
Dr. Nephi Stella
Address: HSC BB1504A
1959 NE Pacific St
Seattle, WA 98195-7280
Phone: 206-221-5220
Fax: 206-543-9520
E-mail: nstella@uw.edu

Running title: ABHD6 and Huntington's disease

Number of Figures: 5

Abbreviations:, 2-arachidonoyl glycerol (**2-AG**); alpha/beta-hydrolase domain containing 6 (**ABHD6**); activity-based protein profiling (**ABPP**), cannabinoid receptor 1 (**CB₁R**); diacylglycerol lipase (**DAGL**), endocannabinoids (**eCB**); fatty acid amide hydrolase (**FAAH**); gamma-aminobutyric acid (**GABA**); Huntington's disease (**HD**); immunohistochemistry (**IHC**); monoacylglycerol lipase (**MAGL**); mutated huntingtin protein (**mtHTT**); medium spiny neurons (**MSN**); semi-quantitative immunohistochemistry (**sqIHC**) and wildtype (**WT**).

Abstract (188 words)

Huntington's Disease is associated with motor behavior deficits that current therapeutics do not alleviate. This pilot study tested if pharmacological inhibition of α/β -hydrolase domain containing 6 (**ABHD6**), a multifunctional enzyme expressed in the striatum, rescues behavioral deficits in HdhQ200/200 mice. Previous work has shown that this model exhibits a reduction in spontaneous locomotion and motor coordination at 8 and 10 months of age, with a more severe phenotype in female mice. Semi-quantitative immunohistochemistry analysis indicated no change in striatal ABHD6 expression at 8 months of age, but a 40% reduction by 10 months in female HdhQ200/200 mice compared to female wild-type (**WT**) littermates. At 8 months of age, acute ABHD6 inhibition selectively rescued motor coordination deficits in female HdhQ200/200 mice without affecting WT performance. ABHD6 inhibition did not impact spontaneous locomotion, grip strength or overall weight in either group, showing that effects were specific to motor coordination. At 10 months of age, semi-chronic ABHD6 inhibition by osmotic pump delivery also rescued motor coordination deficits in female HdhQ200/200 mice without affecting female WT littermates. Our preliminary study suggests that ABHD6 inhibition selectively improves motor performance in female HdhQ200/200 mice.

1. Introduction

Huntington's Disease (**HD**) is characterized by age-dependent deterioration of locomotor and cognitive functions that typically begin during middle age. This fatal neurodegenerative disease is driven by mutated huntingtin proteins (**mtHTT**) produced by excessive CAG repeats in the *HTT* gene. These mutated proteins interfere with normal neuronal functions through a multitude of mechanisms^{1,2}. HD pathological studies showed that mtHTT expression leads to early dysfunction of select genes and proteins in striatal neurons^{3,4}. Considering that few FDA-approved therapeutics are effective for the treatment of HD and most carry the risk of severe side effects, there is an urgent need to better understand the molecular components affected in HD pathogenesis to help develop new therapeutic approaches for safer treatment.

The genetic basis of HD has led to the development of preclinical mouse models that recapitulate molecular mechanisms involved in HD pathogenesis. The HdhQ mouse model was developed using gene targeting technology to insert CAG repeats in the *Hdh* gene, the mouse homolog to *HTT*⁵. Natural germline increases in the expansion of CAG in *Hdh* of the HdhQ150/+ mouse line was leveraged to create several allelic mouse lines, including the HdhQ200/+ and HdhQ200/200 lines^{6,7}. Studies showed that the initial aspects of HD neuropathology and impaired locomotor behavior were detected in the heterozygous HdhQ200/+ line starting at 12 months of age and reached severe impairment by 18 months of age; however, HdhQ200/+ mice maintained a normal life span of approximately 2 years, failing to mimic the reduced life

span characteristic of human adult-onset HD⁸. Our laboratory reported the longitudinal characterization of the behavioral impairment and neuropathological features modeled by the homozygous HdhQ200/200 line⁷. HD pathogenesis was sex-dependent, exhibited an early onset of symptoms through deficits in motor behavior and impaired striatal medium spiny neuron (**MSN**) function at 8 months of age, and was fatal, resulting in a reduced lifespan of 12 months in this model⁷. Female HdhQ200/200 mice displayed a more robust deterioration in spontaneous locomotion and motor coordination, a result that corresponds with human studies showing that women HD patients present with more severe symptoms regardless of CAG expansion size^{9,10}. A more recent study uncovered that there was a significantly higher prevalence of HD in women than men, suggesting a more severe HD pathological process in women¹¹. Thus, the early and more severe onset of impaired motor behavior detected in female HdhQ200/200 mice provides an opportunistic chance to study the involvement of select molecular mechanisms in HD-associated deficits in locomotor behaviors and explore possible avenues for new therapeutics.

The recently discovered multifunctional enzyme α/β -hydrolase domain containing 6 (**ABHD6**) regulates several facets of neuronal functions, including inhibiting neurotransmitter release through the modulation of endocannabinoid (**eCB**) signaling, increasing the amplitude of postsynaptic GABAergic currents through allosteric modulation, and controlling the trafficking and number of post-synaptic AMPA receptors¹². This suggests that changes in ABHD6 expression and activity are likely to regulate neuronal functions in multiple ways. mRNA expression profiling suggests that ABHD6 is particularly abundant in the striatum¹³. We previously developed a rabbit polyclonal antibody that recognizes mouse ABHD6 protein and provided initial immunohistochemistry (**IHC**) evidence that ABHD6 protein is expressed in the striatum¹⁴, however it is unknown how various diseases affect this expression. Recent studies suggest that ABHD6 inhibitors exhibit promising therapeutic efficacy in several preclinical mouse models of neurological diseases, including seizures, traumatic brain injury, and multiple sclerosis¹⁵⁻¹⁸. Importantly, the therapeutic efficacy of ABHD6 inhibitors does not appear to undergo tolerance or trigger overt side-effects, two positive qualities for potential small-molecule therapeutics¹⁸. Therefore, we conducted a pilot study to examine if levels of ABHD6 were affected in HD and tested whether ABHD6 inhibition, either through acute or semi-chronic delivery, can rescue various behavioral deficits in the HdhQ200/200 mouse model.

2. Materials and Methods

2.1 HdhQ200/200 mouse colony.

Mice were housed in a pathogen-free facility in accordance with the National Institutes of Health; the Institutional Animal Care and Use Committee at the University of Washington approved all experiments and in compliance with ARRIVE guidelines. All mice were maintained on a C57BL/6 genetic background. For all HdhQ200/200 experiments, female and male heterozygous HdhQ200/+ knock-in mice were mated to

98 produce homozygous, heterozygous and wild-type littermates. Animals were housed in cages grouped by sex
99 and mixed genotype, had *ad libitum* access to food and water, and were on a 12-hour light/dark cycle.
100 Genotyping was performed with tail snips using primers “cccattcattgcccttgctg” and “gctggctgaggggttga” with
101 a SimpliAmp Thermal Cycler (Thermo Fisher Scientific, Bothell, WA). No sexual dimorphism was detected
102 in the HdhQ200/200 colony (i.e. no differences in litter size or weight)⁷. Mice lacking Abhd6 were generated
103 in collaboration with the TSRI Mouse Genetics Core and the absence of ABHD6 expression validated¹⁹. A
104 total number of ____ animals were used for this study.

105 **2.2 Immunohistochemistry and antibodies.**

106 Mice were euthanized with ketamine/xylazine and perfused with PBS, followed by 4% paraformaldehyde.
107 Brains were extracted and post-fixed in 4% paraformaldehyde at 4°C. Brains were then dehydrated (15%
108 sucrose and then 30% sucrose) and frozen over dry ice. Sagittal sections were cut to a thickness of 30 µm
109 using a sliding microtome and placed in cryoprotectant for storage at -20°C. IHC analysis of each time point
110 group was processed and stained in parallel. For staining, 2 slices per animal were removed from
111 cryoprotectant, washed and incubated at room temperature in blocking buffer. Slices were then transferred to
112 primary staining solutions at 4°C. Sections were then washed and secondary staining was performed using
113 Alexa secondary antibodies at a dilution of 1:500. Additional slices were stained only with secondary staining
114 solutions to serve as non-specific secondary background staining. After secondary staining, sections were
115 washed, mounted on slides and allowed to dry at room temperature overnight. Coverslips were added and
116 sealed with Fluoromount (Sigma, St. Louis, MO) and nail polish. The following antibodies were used in this
117 study: ABHD6¹⁴ and Alexa Fluor 488 (goat/donkey, ThermoFisher).

118 **2.3 Microscopy.**

119 Images were collected on a Marianas microscope (Intelligent Imaging Innovations, Inc. Denver, CO)
120 equipped with either 20x/0.75 NA or 40x/0.75 NA air objective lens with CoolSnap HQ cooled monochrome
121 camera (Photometrics, Tucson, AZ) at the NIDCD Research Core Center at the University of Washington,
122 as previously reported by our laboratory^{20,21}. Noise reduction of images was achieved by deconvolution using
123 SlideBook (Intelligent Imaging Innovations, Inc., Denver, CO). Exposure times were optimized for each
124 antibody to ensure that >99% pixels were within the linear range. Excitation laser of FITC was used to excite
125 excite Alexa 488.

126 **2.4 Semi-quantitative image analysis and statistics.**

127 All images were analyzed using ImageJ (National Institutes of Health) with custom written macros. Macros
128 were applied blindly to each batch of images and analyzed as previously reported by our laboratory²². The
129 mean intensity and standard deviation of each fluorophore were measured, and background signal was
130 removed by thresholding images to mean + standard deviation, corresponding to the top third brightest pixels

in the Gaussian distribution. After thresholding, final measurements were made by taking the mean intensity of the remaining pixels. Values were normalized to the corresponding wild-type sex average.

2.5 Activity-Based Protein Profiling

Mice were euthanized via cervical dislocation and brains dissected and washed with ice cold lysis buffer (0.25M sucrose, 20mM HEPES, 2mM DTT, in deionized H₂O) twice before dounce homogenization. Blood samples and brain tissues were processed using dounce homogenizer and placed on ice for 15 minutes. Tissue homogenates were centrifuged at 800xg for 5 minutes at 4°C. Supernatants were separated to remove debris from unlysed tissue. Supernatants were centrifuged at 100,000xg for 45 minutes at 4°C. Resulting pellet was resuspended in assay buffer (20mM HEPES in deionized H₂O). Proteome concentrations were normalized using Bio-Rad DC protein assay and treated with either HT-01 or FP-Rhodamine at 1uM final concentration for 30 minutes at 37°C. The reaction was quenched using SDS-PAGE loading buffer. After separation by SDS-PAGE (10% acrylamide), samples were visualized by in-gel fluorescence scanning using Chemidoc MP imaging system. Entire blots are depicted.

2.6 Drug treatment and miniature osmotic pump surgery.

KT-182 was synthesized in our laboratory as described²³. For acute studies, mice at 8 months of age were treated with KT-182 (2mg/kg), a dose shown to inhibit brain ABHD6 activity by more than 90% when injected i.p., or with vehicle. Animals were monitored for 1 hour and then behavioral tests were conducted 4 hours post-injection to allow for full inhibition of ABHD6 by KT-182. All animals in the same cage were treated and tested at the same time. For semi-chronic studies, Alzet miniature osmotic pumps (1007D) were used over daily injections to reduce the stress and risk of infection due to daily handling and injection. Buprenorphine and lidocaine were used as analgesic care, and animals were anaesthetized with isoflurane. Pumps were filled with either vehicle or KT-182 and surgically implanted into female HdhQ200/200 and wild-type mice 7 days prior to 10 months of age. Drug was administered at a rate of 0.5 µl/hour to achieve 2mg/kg/day. Only mice undergoing surgery were housed together along with supplemental food mash and gel. Mice were checked on daily and after 5 days post-surgery, mice underwent behavioral studies. We found no significant effect of osmotic pump implantation on motor performance (untreated/HdhQ200/200 data versus vehicle; p=0.631 for male, p=0.618 for female). Thus, the effect of osmotic pump treatments was controlled as both WT and HdhQ200/200 mice received surgery and pumps. A small sample size was chosen due to the timeframe of experiments and initial intention to gather basic evidence.

2.7 HdhQ200/200 behavioral studies.

All animals undergoing testing were used from the same cages, of mixed genotype, and age-matched controls to minimize potential confounding factors. All behavioral studies were performed during the light phase of the light/dark cycle, and the tester was blinded by the conditions and genotype. Cages and equipment were thoroughly cleaned with 70% ethanol and dried between trials. Grip strength was measured by recording the latency to fall when animals were placed on a wire cage top and then inverted. A maximum score of 90 seconds was used. Rotarod (Med Associates Inc., St. Albans, VT) testing included 7 consecutive trials, separated by 15-minute resting periods. The rotational speed used for testing trails began at 4 rpm and increased to 40 rpm for a maximum of 5 minutes, with an acceleration of 0.2 rpm per every 4 seconds. Slow motor learning was measured by the sum of improvement in performance across all 7 trials²⁴. The PhenoTyper (Noldus, Wageningen, the Netherlands) testing consisted of a 72-hour trial where animals were individually housed in a 30 cm × 30 cm Plexiglas cage with *ad libitum* access to water and food. A vertically mounted camera continuously tracked movement and digital traces were analyzed in Ethovision XT 11. Data was taken from the dark phase of day 2 to ensure animals were habituated to the cage and undisturbed by any outside distractions. No exclusion criteria was set for behavioral data and no animals undergoing testing was excluded from the final data set.

2.8 Statistical analyses

Statistical analyses and graphs were generated using GraphPad PRISM 9 (San Diego, CA). Two-way ANOVA with a Bonferroni post-hoc analysis was used for measurements over time and a one-way ANOVA with Tukey's multiple comparison for averaged comparisons. Data were considered significant if $p < 0.05$.

3. Results

3.1 HdhQ200/200 female and male mice do not exhibit overt psychiatric symptoms at 8 and 10 months of age.

We previously reported that female HdhQ200/200 mice exhibited more pronounced deficits in locomotor and motor coordination at 8 months of age compared to male HdhQ200/200 mice⁷. To extend these results, we studied anxiety-like and depressive-like behaviors by measuring both thigmotaxis and time spent in the hidden zone of the home-cage during the dark phase using the PhenoTyper^{20,25}. We found no difference in the time spent in the thigmotaxis or hidden zone by either male or female HdhQ200/200 mice when compared to their respective wild-type littermates (**Supplementary Fig. 1A-F**). Importantly, the frequency to enter either the thigmotaxis but not the hidden zone was significantly decreased for female HdhQ200/200 mice when compared to female wild-type littermates at 8 months of age (**Supplementary Fig. 2A-F**). This impairment was not detected when comparing male HdhQ200/200 and male WT mice. Considering that the total times spent in each area was comparable for all genotypes, a decrease in frequency to enter the

195 thigmotaxis can be attributed to decreased general locomotion in female HdhQ200/200 mice rather than
196 evidence for an anxious or depressive phenotype, such as lack of motivation. Base on this premise, we focused
197 the subsequent studies on locomotor and motor coordination impairments.

198 3.2 At 8 months of age, acute ABHD6 inhibition rescued motor coordination deficits in female 199 HdhQ200/200 mice and improved motor coordination in male WT mice.

200 We studied the effect of acute ABHD6 inhibition on HdhQ200/200 mice and WT littermates of both sexes
201 at 8 months of age, an age when motor behavior deficits are pronounced in female but absent in male
202 HdhQ200/200 mice⁷. To measure deficits in both motor coordination and acquisition of new motor skills,
203 we measured the latency to fall off a rotarod over multiple trials²⁴. As previously reported, female
204 HdhQ200/200 performed 43% worse than female WT littermates ($p=0.030$) (**Fig. 1A**)⁷. To pharmacologically
205 inhibit brain ABHD6 activity, we treated mice with KT-182, a brain-penetrant compound shown to reduce
206 brain ABHD6 activity by more than 90%²³. **Figures 1B-C** show that KT-182 did not affect the performance
207 of female WT mice and yet greatly improved the performance of female HdhQ200/200 mice. Thus, acute
208 treatment with KT-182 rescued this deficit in female HdhQ200/200 mice by 65% ($p<0.001$) without
209 influencing the rotarod performance of female WT mice (**Fig. 1A**). Interestingly, female HdhQ200/200 mice
210 treated with KT-182 performed far better in the initial trials than female WT mice treated with KT-182 ($F_{(1, 95)}=121.7$, $p<0.001$) (**Fig. 1C**). These results show that acute ABHD6 inhibition did not affect motor
212 coordination of female WT mice but rescued the motor coordination deficits caused by mtHTT in female
213 HdhQ200/200 mice tested at 8 months of age.

214 To determine the effect of acute ABHD6 inhibition on the acquisition of new motor skills, we adopted a
215 method in which slow motor learning was measured by the sum of improvement in performance across all
216 trials²⁴. **Figure 1D** shows that slow motor learning was similar between female HdhQ200/200 and WT mice
217 and that acute KT-182 treatment did not affect this measure. Thus, at 8 months of age, acute ABHD6
218 inhibition rescued motor coordination deficits in female HdhQ200/200 mice and this immediate therapeutic
219 response remained evident across all 7 trials. By contrast, acute ABHD6 inhibition did not affect motor
220 coordination in female WT mice and did not affect slow motor learning in either group, showing that rescue
221 was specific to deficits in motor coordination that develop in female HdhQ200/200 mice.

222 As previously reported, male HdhQ200/200 mice performed similarly to male WT littermates in motor
223 coordination at 8 months of age (**Supplementary Fig. 3A**)⁷. Remarkably, KT-182 improved motor
224 performance of male WT mice by 2-fold ($p=0.001$) and yet did not affect the performance of male
225 HdhQ200/200 mice (**Supplementary Fig. 3A**). The KT-182 response improved over all trials in male WT
226 mice ($F_{(1, 50)}=97.85$, $p<0.01$) (**Supplementary Fig. 3B**) but was absent in male HdhQ200/200 mice
227 (**Supplementary Fig. 3C**). Accordingly, KT-182 also improved slow motor learning in male WT mice

228 (p=0.005) but not in male HdhQ200/200 mice (**Supplementary Fig. 3D**). These results show that acute
229 ABHD6 inhibition improves motor coordination in male WT mice but does not affect motor coordination
230 in male HdhQ200/200 mice tested at 8 months of age.

231 Based on this result, we focused our pilot study on female HdhQ200/200 mice. Previous experiments
232 suggested that acute treatment of female HdhQ200/200 mice at 10 months of age with KT-182 did not affect
233 their pronounced deficit in motor coordination (data not shown), indicating that a prolonged treatment
234 approach at a greater symptomatic stage might be required to test the effects of ABHD6 inhibition.

235 3.3 Striatal ABHD6 expression in female HdhQ200/200 mice remained unchanged at 8 months of 236 age but was reduced by 10 months of age.

237 To determine if ABHD6 expression changes in the striatum of HdhQ200/200 mice, we used a purified rabbit
238 polyclonal antibody that recognizes a 38 amino acid epitope in mABHD6 and had been previously validated
239 by our laboratory¹⁴. To further rigorously validate this new affinity-purified antibody, we immunostained brain
240 coronal sections from WT and ABHD6-knockout mice¹⁹. **Figures 2A-B** illustrate ABHD6 expression in
241 mouse dorsal striatum and suggest enhanced expression in select striatal cells. **Figure 2C** validates the
242 selectivity of the antibody by confirming the absence of immunofluorescence signal in sections from ABHD6-
243 knockout mice.

244 Motor coordination is significantly impaired in female HdhQ200/200 mice at both 8 and 10 months of
245 age⁷. To determine if ABHD6 expression is also affected by HD pathogenesis, we immunostained brain
246 coronal sections of female HdhQ200/200 mice and WT littermates at 8 and 10 months of age and measured
247 striatal ABHD6 expression levels with semi-quantitative immunohistochemistry (**sqIHC**) as previously
248 described by our laboratory^{7,18,22}. We found no difference in ABHD6 expression between female
249 HdhQ200/200 and WT striatum at 8 months of age but a significant 40% decrease in expression at 10 months
250 of age ($F_{(1,15)}=5.59$, $p=0.032$) (**Fig. 2D**). **Figures 2E-H** show representative images of IHC staining of
251 ABHD6 expression in the striatum of female HdhQ200/200 and WT mice at 8 and 10 months of age and
252 illustrates reduced ABHD6 expression in female HdhQ200/200 at 10 months of age. Thus, striatal ABHD6
253 expression in female HdhQ200/200 mice decreases late in the disease (i.e. after symptom onset and before
254 end-stage).

255 3.3 Semi-chronic treatment with KT-182 safely blocked brain ABHD6 activity.

256 The reduction in striatal ABHD6 expression in female HdhQ200/200 mice at 10 months of age suggests that
257 a semi-chronic treatment with KT-182 is preferable. Thus, we sought to use miniature osmotic pumps as a
258 semi-chronic delivery system. Mice were surgically implanted with an Alzet® miniature osmotic pump
259 containing KT-182 that enables constant drug delivery for 7 days. While it is known that KT-182 crosses the

260 blood-brain-barrier²³, its effectiveness in inhibiting ABHD6 following administration via osmotic pumps has
261 yet to be determined. We validated this approach using competitive activity-based protein profiling (ABPP)
262 with the fluorescence probe HT-01²⁶. Brain ABHD6 activity was drastically reduced in WT mice after 7 days
263 of KT-182 administration (**Fig. 3A**). Inhibition appeared to be selective to ABHD6, as activities of other
264 lipid-degrading enzymes (such as fatty acid amid hydrolase (**FAAH**) and diacylglycerol lipase (**DAGL**)) were
265 not inhibited in drug-treated animals. Furthermore, ABHD6 activity in blood samples was undetectable in
266 KT-182 treated mice (data not shown). Importantly, female HdhQ200/200 mice and WT littermates carrying
267 osmotic pumps with vehicle or KT-182 for 7 days at 10 months of age did not show overt side effects. This
268 treatment regimen did not affect the overall weight or grip strength in mice (**Fig. 3B-C**), nor were any other
269 behavioral changes observed. These results show that osmotic pump delivery of KT-182 for 7 days achieves
270 near-complete inhibition of ABHD6 in the brain without triggering overt side effects in WT and symptomatic
271 HdhQ200/200 female mice.

272 **3.4 At 10 months of age, semi-chronic ABHD6 inhibition rescued motor coordination deficit in** 273 **female HdhQ200/200 mice.**

274 As previously reported, motor coordination was decreased by 31% in female HdhQ200/200 mice compared
275 to WT littermates at 10 months of age ($p=0.046$) (**Fig. 4A**)⁷. **Figures 4A-C** show that KT-182 did not affect
276 the motor performance of female WT mice but greatly improved the performance of female HdhQ200/200
277 mice ($F_{(1, 70)}=33.53$, $p<0.001$). Thus, semi-chronic treatment with KT-182 rescued this deficit selectively in
278 symptomatic HdhQ200/200 mice by 53% to be comparable to WT levels ($p=0.019$) (**Fig. 4A**). Slow motor
279 learning was similar between female HdhQ200/200 mice and WT littermates treated with vehicle, as
280 previously reported⁷, and semi-chronic inhibition of ABHD6 did not affect this (**Fig. 4D**). Thus, at 10 months
281 of age, semi-chronic ABHD6 inhibition rescued motor coordination deficits in female HdhQ200/200 mice
282 but did not affect motor coordination in female WT mice or slow motor learning in either group, showing
283 that rescue at 10 months of age was specific to deficits in motor coordination that develop in this HD mouse
284 model.

285 **3.5 At 10 months of age, semi-chronic inhibition of ABHD6 did not affect spontaneous locomotion** 286 **of female HdhQ200/200 mice and wild-type littermates.**

287 To determine if semi-chronic inhibition of ABHD6 might affect general locomotion, we measured
288 spontaneous locomotion of female WT and HdhQ200/200 mice using the PhenoTyper. As previously
289 reported, female HdhQ200/200 mice and WT littermates exhibited similar exploratory behavior of a novel
290 environment (as measured by the distance traveled during the first hour of being placed into the chamber)^{7,27}
291 (**Fig. 5A**). As expected, female HdhQ200/200 mice exhibited reduced spontaneous locomotion during the

dark phase (when mice are more active) compared to female WT mice ($p=0.040$), yet similar spontaneous locomotion during the light phase (when mice are less active) compared to female WT mice at 10 months of age (**Fig. 5B-C**). Semi-chronic inhibition of ABHD6 did not affect these behaviors in both groups during either phase (**Fig. 5A-C**). These results confirm our previous study showing that female HdhQ200/200 mice are less active during the dark compared to female WT mice and show that spontaneous locomotion in both groups is unaffected by semi-chronic inhibition of ABHD6.

4. Discussion

Our current study shows preliminary data that the pharmacological inhibition of ABHD6 through osmotic pump delivery rescues motor coordination deficits in female HdhQ200/200 mice, a mouse model of HD that exhibits robust early onset deficits in multiple motor behaviors compared to female WT littermates. Markedly, ABHD6 inhibition rescued deficits in motor coordination without affecting other deficits in locomotion exhibited by female HdhQ200/200 mice. Furthermore, ABHD6 inhibition did not cause overt side effects (i.e., change in overall weight, grip strength, novel environment exploration and spontaneous locomotion during the light phase, or changes in observed behaviors), suggesting a promising safety profile for this class of compounds. Using a validated rabbit polyclonal antibody that recognizes ABHD6 in mouse tissue, we found that ABHD6 expression remains unchanged in female HdhQ200/200 mice at 8 months of age compared to WT littermates but is reduced by 10 months of age. The interaction that we report here suggests several possible molecular mechanisms that could link the reduction in striatal ABHD6 expression and selective rescue of motor coordination deficits in female HdhQ200/200 mice.

The expression and function of many genes and proteins change as a result of mtHTT during HD pathogenesis²⁸, including several other serine hydrolases that control the eCB signaling system^{29,30}. The activity of FAAH, DAGL and N-acylphosphatidylethanolamine-specific phospholipase D change in the striatum of R6/2 mice in relation to disease progression, whereas monoacylglycerol lipase (**MAGL**) activity is unchanged compared to WT mice^{31,32}. In HD43 cells in culture, inducible expression of mtHTT reduces FAAH activity and increases MAGL activity³¹. In primary mouse striatal astrocytes, mtHTT expression increases MAGL mRNA levels without changing FAAH³³. Other examples of changes in serine hydrolase activities associated with HD pathogenesis include acetylcholinesterase³⁴, palmitoyl acyltransferase^{35,36} and transglutaminase 2³⁷. Here, we report the downregulation of ABHD6 expression in female HdhQ200/200 mice, adding a new serine hydrolase to the list of eCB enzymes affected by HD pathogenesis.

Considering the expression pattern of ABHD6 in the striatum and range of signaling mechanisms that this enzyme modulates, reduced expression of ABHD6 in HdhQ200/200 striatum detected at 10 months of age is likely to affect multiple aspects of neuronal function beyond its ability to control eCB signaling, including

324 post-synaptic GABAergic currents and trafficking of AMPA receptors to the plasma membrane¹². We show
325 that ABHD6 is expressed at higher levels in select striatal cells with neuronal-like morphology, which agrees
326 with the single-cell RNA-seq analyses of mouse striatum showing that ABHD6 mRNA expression is abundant
327 in interneurons¹³ (<http://www.brainrnaseq.org/>). Considering the role of striatal interneurons in the control
328 of cortico-striatal projections and how their functions are impaired by HD pathogenesis³⁸⁻⁴⁰, ABHD6 down-
329 regulation might contribute to symptoms measured in HdhQ200/200 mice at 10 months of age by disrupting
330 the functionality of the cortico-striatal projections.

331 Few therapeutic approaches designed to target serine hydrolases have been tested in HD mouse models.
332 Promising results have been reported for the pharmacological inhibition of the serine protease HTRA2⁴¹ and
333 transglutaminase 2³⁷, and a recent study validated MAGL expressed by astrocytes as a potential therapeutic
334 target for HD³³. Our results add to this body of knowledge by showing that ABHD6 inhibition rescued a
335 specific, early onset symptom – motor coordination – in female HdhQ200/200 mice, providing a new
336 therapeutic approach for the treatment of select symptoms associated with HD. In addition, due to the lack
337 of depressive or anxious phenotype in the HdhQ200/200 model, we can conclude that this rescue was select
338 for motor behaviors and not through motivation or other psychiatric symptoms. Our pilot study also
339 emphasizes the need to test and optimize dosing regimens of ABHD6 inhibition as a function of disease
340 progression as we found that semi-chronic, but not acute, inhibition of ABHD6 was required to rescue deficits
341 in motor coordination in HdhQ200/200 mice at 10 months of age.

342 We can draw at least two potential molecular and cellular mechanisms by which ABHD6 inhibition might
343 rescue motor coordination in female HdhQ200/200 mice. First, serine hydrolases are one of the largest known
344 classes of enzymes, each with remarkably different enzymatic activities performed by the common defining
345 molecular characteristic of a nucleophilic serine in the active site⁴². The pocket formed by the catalytic site of
346 ABHD6 hydrolyzes select monoacylglycerols (including the eCB 2-arachidonoyl glycerol (**2-AG**)), and
347 carbamate-based inhibitors (such as KT-182) block the hydrolyzing activity through a covalent modification
348 of the catalytic Ser148^{23,43-45}. Thus, inhibition of the ABHD6 catalytic triad mediated-activity favors 2-AG
349 accumulation in post-synaptic compartments of active neurons, which in turn enhances both CB₁R-mediated
350 presynaptic inhibition of neurotransmitters release and post-synaptic GABAergic currents¹². By contrast, the
351 ability of ABHD6 to control the number of AMPA receptors trafficking to the plasma membrane does not
352 involve the catalytic triad⁴⁶, and thus the rescue of motor coordination deficit in HdhQ200/200 by KT-182 is
353 unlikely to involve this AMPA receptor-dependent mechanism. Second, at 8 months of age, when striatal
354 ABHD6 expression is similar in WT and HdhQ200/200 mice, acute ABHD6 inhibition enhanced rotarod
355 coordination in female HdhQ200/200 mice but not in WT littermates. This result suggests the existence of a
356 molecular mechanism, or lack of molecular mechanism, that is present in female HdhQ200/200 mice and not

in female WT mice that enables ABHD6 inhibition to improve motor coordination only in female HdhQ200/200 mice. Thus, our study suggests the following picture whereby inhibition of striatal ABHD6 influences the function of defective cortico-striatal pathways in female HdhQ200/200 mice in such a way to rescue deficits in motor coordination³⁸⁻⁴⁰.

Our preliminary studies on acute ABHD6 inhibition led to a remarkable increase in motor coordination measured in male WT mice at 8 months of age but not male HdhQ200/200 mice. While the molecular mechanism of this response remains to be studied, two conclusions can be drawn from this result: male WT mice express molecular components that enhance the efficacy of acute ABHD6 inhibition to regulate motor coordination, and these molecular components are absent in male HdhQ200/200 mice at 8 months of age. Further studies are needed to tease apart this difference.

Few treatments are available to help HD patients manage the multiple debilitating symptoms that arise as a function of disease progression. Here, we provide the first preliminary evidence that pharmacological inhibition of ABHD6 selectively rescues deficits in motor coordination modeled by female HdhQ200/200 mice. Our results suggest a mechanistic link between the reduction in striatal ABHD6 expression and selective rescue of motor coordination deficits in female HdhQ200/200 mice. Thus, ABHD6 inhibitors represent promising pharmacological tools to unravel the molecular mechanisms involved in motor coordination deficits in neurological diseases and could lead to the development of a new therapeutic modality to treat deficits in locomotor behaviors associated with HD.

Acknowledgments: This work was supported by the National Institutes of Health (T32 MH015442 to JK. C., DA043571 to K-L. H., DA037673 and DA011322 to K.M. and DA026430 to N.S.).

Author contributions: JKC and NS designed studies and wrote manuscript. JKC and KV performed behavioral tests. JKC and RW performed imaging studies. MS performed assays. KLS and KM provided expertise support. NS supervised project.

Figure Legends

Figure 1: At 8 months of age, acute inhibition of ABHD6 rescued motor coordination deficits in female HdhQ200/200 mice.

Motor coordination was measured using rotarod analysis in wild type (WT) and HdhQ200/200 mice (8 months of age) that were acutely treated with either vehicle or KT-182. **A.** Analysis of the average latency to fall showed that KT-182 did not affect motor coordination in female WT mice but significantly rescued motor coordination in female HdhQ200/200 mice. Statistical analysis: One-way ANOVA analysis (multiple comparisons using Tukey) indicated a 49% reduction in latency to fall in HdhQ200/200 mice compared to

WT mice and a 58% rescue of latency to fall in HdhQ200/200 mice with KT-182. **B-C.** KT-182 treatment did not affect latency to fall in (B) female WT mice and enhanced latency to fall in (C) female HdhQ200/200 mice across all trials. Statistical analysis: Two-way ANOVA with a Bonferroni post-hoc analysis indicated significant rescue of motor coordination deficit in HdhQ200/200 by KT-182 compared to vehicle-treated HdhQ200/200 mice. **D.** Slow motor learning was comparable between female HdhQ200/200 mice and WT littermates, and unaffected by acute treatment of KT-182. N = 6-11 mice per condition, error bars represent S.E.M. and * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Figure 2: Reduced striatal ABHD6 expression in female HdhQ200/200 mice compared to wild-type mice at 10 months of age.

Immunohistochemistry (IHC) analysis of ABHD6 expression in mouse striatum using rabbit polyclonal antibodies that recognize mABHD6 showed no change between wild-type (WT) and HdhQ200/200 female mice at 8 months of age but a decrease in ABHD6 expression in HdhQ200/200 mice at 10 months of age. **A.** Representative IHC images show discreet ABHD6 expression in WT mouse striatum (12 weeks of age). Scale bar = 50 μ m. **B.** Representative IHC images show higher expression of ABHD6 in select striatal cells. Scale bar = 25 μ m. **C.** Validation of antibody selectivity via IHC staining showed no immunostaining in *Abhd6*^{-/-} mouse striatum (12 weeks of age). Scale bar = 25 μ m. **D.** Semi-quantitative IHC analysis of ABHD6 expression in WT and HdhQ200/200 showed no change at 8 months of age but significant decrease at 10 months of age in HdhQ200/200 mice. Statistical analysis: Two-way ANOVA with a Bonferroni post-hoc analysis indicated no difference at 8 months of age but a 40% decrease at 10 months of age. **E-H.** Representative striatal ABHD6 IHC staining at (E) 8 months of age in female WT and (F) HdhQ200/200 mice and (G) 10 months of age in female WT and (H) HdhQ200/200 mice. Scale bar = 50 μ m. N = 4-5 mice per condition, error bars represent S.E.M. and * $p < 0.05$.

Figure 3: Semi-chronic, subcutaneous, osmotic pump delivery of KT-182 resulted in on-target inhibition of brain ABHD6 activity and did not affect overall body weight or grip strength of wild-type and HdhQ200/200 mice at 10 months of age.

Osmotic pumps delivering KT-182 were implanted subcutaneously (s.c.) in wild-type (WT) mice (12 weeks of age) for 10 days and ABHD6 activity was measured by activity base protein profiling. **A.** 10 days s.c. osmotic delivery of KT-182 (lanes K1, K2 and K3) inhibited brain ABHD6 activity compared to vehicle-treated animals (lanes VEH1, VEH2 and VEH3) without affecting DAGLa, DAGLb and FAAH activity. N = 3 mice per treatment. **B-C.** Semi-chronic inhibition of ABHD6 did not affect (B) weight loss or (C) grip strength as measured by the inverted wire test of HdhQ200/200 mice compared to WT mice (10 months of age).

421 Statistical analysis: One-way ANOVA analysis (multiple comparisons using Tukey) indicated significant
422 reduction in overall body weight of HdhQ200/200 mice compared to WT and no significant difference in
423 grip strength. N = 5-8 mice per condition, error bars represent S.E.M. and * $p < 0.05$.

424

425 **Figure 4: Semi-chronic inhibition of ABHD6 rescued motor coordination deficits in HdhQ200/200**
426 **mice at 10 months of age.**

427 Motor coordination was measured in female wild type (WT) and HdhQ200/200 mice (10 months of age) that
428 were implanted with osmotic pumps delivering either vehicle or KT-182. **A.** Analysis of average latency to fall
429 from the rotarod measured across 7 trials showed that KT-182 did not affect motor coordination in WT mice
430 but significantly rescued motor coordination in HdhQ200/200 mice. Statistical analysis: One-way ANOVA
431 analysis (multiple comparisons using Tukey) indicated a 31% reduction in latency to fall in HdhQ200/200
432 mice compared to WT mice and a 53% rescue of latency to fall in HdhQ200/200 mice when treated with KT-
433 182. **B.** KT-182 treatment did not affect latency to fall in WT mice but **C.** enhanced latency to fall in
434 HdhQ200/200 mice. Statistical analysis: Two-way ANOVA analysis with Bonferroni post-hoc analysis
435 indicated significant rescue of motor coordination deficits in HdhQ200/200 by KT-182 compared to vehicle-
436 treated HdhQ200/200 mice. **D.** Slow motor learning was comparable between HdhQ200/200 mice and WT
437 littermates and not affected by treatment with KT-182. N = 6-7 mice per condition, error bars represent
438 S.E.M. and * $p < 0.05$, ** $p < 0.01$.

439

440 **Figure 5: Semi-chronic inhibition of ABHD6 did not affect spontaneous locomotion of wild-type and**
441 **HdhQ200/200 mice at 10 months of age.**

442 Spontaneous locomotion (meters/hour) was measured in female wild type (WT) and HdhQ200/200 mice (10
443 months of age) that were implanted with osmotic pumps delivering either vehicle or KT-182 using
444 PhenoTyper chambers. **A.** Distance traveled during the first hour of entering the PhenoTyper chamber
445 indicates exploration of a novel environment and was unaffected by genotype or KT-182 treatment. Distance
446 traveled measured during the **B.** dark phase (high activity, 12 hours) and **C.** light phase (low activity, 12 hours).
447 Statistical analysis: One-way ANOVA analysis (multiple comparisons using Tukey) indicated a 41% reduction
448 in spontaneous locomotion in HdhQ200/200 compared to WT measured during the dark phase but no
449 difference between vehicle and KT-182. N = 6 mice per condition, error bars represent S.E.M. and * $p < 0.05$.

450

451

References

Landles, C. & Bates, G. P. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. *EMBO Rep* **5**, 958-963, doi:10.1038/sj.embor.7400250 (2004).

Ross, C. A. & Tabrizi, S. J. Huntington's disease: from molecular pathogenesis to clinical treatment. *Lancet Neurol* **10**, 83-98, doi:10.1016/S1474-4422(10)70245-3 (2011).

Roze, E. *et al.* in *Frontiers in neuroanatomy* Vol. 5 (Frontiers Media SA, 2011).

Walker, F. O. in *Lancet* Vol. 369 218-228 (Elsevier, 2007).

Lin, C.-H. *et al.* in *Human Molecular Genetics* Vol. 10 137-144 (Oxford Univ Press, 2001).

Pouladi, M. A., Morton, A. J. & Hayden, M. R. Choosing an animal model for the study of Huntington's disease. *Nat Rev Neurosci* **14**, 708-721, doi:10.1038/nrn3570 (2013).

Cao, J. K., Viray, K., Zweifel, L. & Stella, N. Sex-dependent impaired locomotion and motor coordination in the HdhQ200/200 mouse model of Huntington's Disease. *Neurobiology of disease* **132**, 104607 (2019).

Heng, M. Y. *et al.* Early autophagic response in a novel knock-in model of Huntington disease. *Hum Mol Genet* **19**, 3702-3720, doi:10.1093/hmg/ddq285 (2010).

Pearl, J. R. *et al.* Enhanced retinal responses in Huntington's disease patients. *Journal of Huntington's disease* **6**, 237-247 (2017).

Zielonka, D. *et al.* The influence of gender on phenotype and disease progression in patients with Huntington's disease. *Parkinsonism & related disorders* **19**, 192-197 (2013).

Zielonka, D. & Stawinska-Witoszynska, B. Gender Differences in Non-sex Linked Disorders: Insights From Huntington's Disease. *Frontiers in Neurology* **11**, 859-855, doi:10.3389/fneur.2020.00571 (2020).

Cao, J. K., Kaplan, J. & Stella, N. ABHD6: Its Place in Endocannabinoid Signaling and Beyond. *Trends in pharmacological sciences* (2019).

Gokce, O. *et al.* Cellular Taxonomy of the Mouse Striatum as Revealed by Single-Cell RNA-Seq. *Cell Rep* **16**, 1126-1137, doi:10.1016/j.celrep.2016.06.059 (2016).

Marrs, W. R. *et al.* The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. *Nat Neurosci* **13**, 951-957, doi:10.1038/nn.2601 (2010).

Tchantchou, F. & Zhang, Y. Selective Inhibition of Alpha/Beta-Hydrolase Domain 6 Attenuates Neurodegeneration, Alleviates Blood Brain Barrier Breakdown, and Improves Functional Recovery in a Mouse Model of Traumatic Brain Injury. *Journal of Neurotrauma* **30**, 565-579, doi:10.1089/neu.2012.2647 (2013).

Wen, J., Ribeiro, R., Tanaka, M. & Zhang, Y. Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis. *Neuropharmacology* **99**, 196-209, doi:10.1016/j.neuropharm.2015.07.010 (2015).

Manterola, A. *et al.* Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination. *Biochemical pharmacology*, doi:10.1016/j.bcp.2018.07.042 (2018).

Naydenov, A. V. *et al.* ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6/2 mice. *Neuron* **83**, 361-371, doi:10.1016/j.neuron.2014.06.030 (2014).

Van Esbroeck, A. C. M. *et al.* Identification of α , β -hydrolase domain containing protein 6 as a diacylglycerol lipase in Neuro-2a cells. *Frontiers in molecular neuroscience* **12**, 286 (2019).

Cao, J. K., Detloff, P. J., Gardner, R. G. & Stella, N. Sex-dependent behavioral impairments in the HdhQ350/+ mouse line. *Behav Brain Res* **337**, 34-45, doi:10.1016/j.bbr.2017.09.026 (2018).

Cao, J. K., Viray, K., Zweifel, L. & Stella, N. Sex-dependent impaired locomotion and motor coordination in the HdhQ200/200 mouse model of Huntington's Disease. *Neurobiology of Disease* **132**, 104607, doi:10.1016/j.nbd.2019.104607 (2019).

Horne, E. A. *et al.* Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models. *Eur J Neurosci* **37**, 429-440, doi:10.1111/ejn.12045 (2013).

Hsu, K.-L. *et al.* Discovery and optimization of piperidyl-1, 2, 3-triazole ureas as potent, selective, and in vivo-active inhibitors of α/β -hydrolase domain containing 6 (ABHD6). *Journal of medicinal chemistry* **56**, 8270-8279 (2013).

Costa, R. M., Cohen, D. & Nicolelis, M. A. L. in *Current Biology* Vol. 14 1124-1134 (2004).

Steele, A. D., Jackson, W. S., King, O. D. & Lindquist, S. The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases. *Proc Natl Acad Sci U S A* **104**, 1983-1988, doi:0610779104 [pii] 10.1073/pnas.0610779104 (2007).

Hsu, K.-L. *et al.* DAGL β inhibition perturbs a lipid network involved in macrophage inflammatory responses. *Nature chemical biology* **8**, 999 (2012).

Steinbach, J. M., Garza, E. T. & Ryan, B. C. Novel Object Exploration as a Potential Assay for Higher Order Repetitive Behaviors in Mice. *J Vis Exp*, doi:10.3791/54324 (2016).

Luthi-Carter, R. *et al.* Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. *Hum Mol Genet* **9**, 1259-1271, doi:10.1093/hmg/ddd139 [pii] (2000).

Friedman, D., French, J. A. & Maccarrone, M. Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. *The Lancet Neurology* **18**, 504-512 (2019).

Aymerich, M. S. *et al.* Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. *Biochemical pharmacology* **157**, 67-84 (2018).

Bari, M. *et al.* In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system. *The FEBS journal* **280**, 3376-3388 (2013).

Blazquez, C. *et al.* Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. *Brain* **134**, 119-136, doi:10.1093/brain/awq278 [pii] (2011).

514 10.1093/brain/awq278 (2011).
 515 33 Ruiz-Calvo, A. *et al.* Astroglial monoacylglycerol lipase controls mutant huntingtin-induced damage of striatal neurons.
 516 *Neuropharmacology* (2019).
 517 34 Ferrante, R. J., Beal, M. F., Kowall, N. W., Richardson Jr, E. P. & Martin, J. B. Sparing of acetylcholinesterase-containing striatal
 518 neurons in Huntington's disease. *Brain research* **411**, 162-166 (1987).
 519 35 Sanders, S. S. & Hayden, M. R. (Portland Press Ltd., 2015).
 520 36 Rush, D. B., Leon, R. T., McCollum, M. H., Treu, R. W. & Wei, J. Palmitoylation and trafficking of GAD65 are impaired in a cellular
 521 model of Huntington's disease. *Biochemical Journal* **442**, 39-48 (2012).
 522 37 Prime, M. E. *et al.* Discovery and structure–activity relationship of potent and selective covalent inhibitors of transglutaminase 2
 523 for Huntington's disease. *Journal of medicinal chemistry* **55**, 1021-1046 (2012).
 524 38 Cicchetti, F., Prensa, L. a., Wu, Y. & Parent, A. Chemical anatomy of striatal interneurons in normal individuals and in patients with
 525 Huntington's disease. *Brain research reviews* **34**, 80-101 (2000).
 526 39 Cepeda, C. *et al.* Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models. *Journal*
 527 *of Neuroscience* **33**, 7393-7406 (2013).
 528 40 Reiner, A. & Deng, Y. P. Disrupted striatal neuron inputs and outputs in Huntington's disease. *CNS neuroscience & therapeutics*
 529 **24**, 250-280 (2018).
 530 41 Goffredo, D. *et al.* Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington's Disease.
 531 *Pharmacological research* **52**, 140-150 (2005).
 532 42 Liu, Y., Patricelli, M. P. & Cravatt, B. F. Activity-based protein profiling: the serine hydrolases. *Proc Natl Acad Sci U S A* **96**, 14694-
 533 14699 (1999).
 534 43 Blankman, J. L., Simon, G. M. & Cravatt, B. F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-
 535 arachidonoylglycerol. *Chem Biol* **14**, 1347-1356 (2007).
 536 44 Kaczor, A. A. *et al.* Comparative molecular field analysis and molecular dynamics studies of α/β hydrolase domain containing 6
 537 (ABHD6) inhibitors. *Journal of molecular modeling* **21**, 250, doi:10.1007/s00894-015-2789-8 (2015).
 538 45 Bowman, A. L. & Makriyannis, A. Highly Predictive Ligand-based Pharmacophore and Homology Models of ABHD6. *Chemical*
 539 *biology & drug design* **81**, 382-388 (2013).
 540 46 Wei, M. *et al.* α/β -Hydrolase domain-containing 6 (ABHD6) negatively regulates the surface delivery and synaptic function of
 541 AMPA receptors. *Proceedings of the National Academy of Sciences* **113**, E2695-E2704 (2016).
 542

Figures

Figure 1

At 8 months of age, acute inhibition of ABHD6 rescued motor coordination deficits in female HdhQ200/200 mice. Motor coordination was measured using rotarod analysis in wild type (WT) and HdhQ200/200 mice (8 months of age) that were acutely treated with either vehicle or KT-182. A. Analysis of the average latency to fall showed that KT-182 did not affect motor coordination in female WT mice but significantly rescued motor coordination in female HdhQ200/200 mice. Statistical analysis: One-way

ANOVA analysis (multiple comparisons using Tukey) indicated a 49% reduction in latency to fall in HdhQ200/200 mice compared to WT mice and a 58% rescue of latency to fall in HdhQ200/200 mice with KT-182. B-C. KT-182 treatment did not affect latency to fall in (B) female WT mice and enhanced latency to fall in (C) female HdhQ200/200 mice across all trials. Statistical analysis: Two-way ANOVA with a Bonferroni post-hoc analysis indicated significant rescue of motor coordination deficit in HdhQ200/200 by KT-182 compared to vehicle-treated HdhQ200/200 mice. D. Slow motor learning was comparable between female HdhQ200/200 mice and WT littermates, and unaffected by acute treatment of KT-182. N = 6-11 mice per condition, error bars represent S.E.M. and * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Figure 2

Reduced striatal ABHD6 expression in female HdhQ200/200 mice compared to wild-type mice at 10 months of age. Immunohistochemistry (IHC) analysis of ABHD6 expression in mouse striatum using rabbit polyclonal antibodies that recognize mABHD6 showed no change between wild-type (WT) and HdhQ200/200 female mice at 8 months of age but a decrease in ABHD6 expression in HdhQ200/200 mice at 10 months of age. A. Representative IHC images show discrete ABHD6 expression in WT mouse

striatum (12 weeks of age). Scale bar = 50 mm. B. Representative IHC images show higher expression of ABHD6 in select striatal cells. Scale bar = 25 mm. C. Validation of antibody selectivity via IHC staining showed no immunostaining in *Abhd6*^{-/-} mouse striatum (12 weeks of age). Scale bar = 25 mm. D. Semi-quantitative IHC analysis of ABHD6 expression in WT and *HdhQ200/200* showed no change at 8 months of age but significant decrease at 10 months of age in *HdhQ200/200* mice. Statistical analysis: Two-way ANOVA with a Bonferroni post-hoc analysis indicated no difference at 8 months of age but a 40% decrease at 10 months of age. E-H. Representative striatal ABHD6 IHC staining at (E) 8 months of age in female WT and (F) *HdhQ200/200* mice and (G) 10 months of age in female WT and (H) *HdhQ200/200* mice. Scale bar = 50 mm. N = 4-5 mice per condition, error bars represent S.E.M. and *p < 0.05.

Figure 3

Semi-chronic, subcutaneous, osmotic pump delivery of KT-182 resulted in on-target inhibition of brain ABHD6 activity and did not affect overall body weight or grip strength of wild-type and *HdhQ200/200*

mice at 10 months of age. Osmotic pumps delivering KT-182 were implanted subcutaneously (s.c.) in wild-type (WT) mice (12 weeks of age) for 10 days and ABHD6 activity was measured by activity base protein profiling. A. 10 days s.c. osmotic delivery of KT-182 (lanes K1, K2 and K3) inhibited brain ABHD6 activity compared to vehicle-treated animals (lanes VEH1, VEH2 and VEH3) without affecting DAGLa, DAGLb and FAAH activity. N = 3 mice per treatment. B-C. Semi-chronic inhibition of ABHD6 did not affect (B) weight loss or (C) grip strength as measured by the inverted wire test of HdhQ200/200 mice compared to WT mice (10 months of age). Statistical analysis: One-way ANOVA analysis (multiple comparisons using Tukey) indicated significant reduction in overall body weight of HdhQ200/200 mice compared to WT and no significant difference in grip strength. N = 5-8 mice per condition, error bars represent S.E.M. and *p < 0.05.

Figure 4

Semi-chronic inhibition of ABHD6 rescued motor coordination deficits in HdhQ200/200 mice at 10 months of age. Motor coordination was measured in female wild type (WT) and HdhQ200/200 mice (10 months of age) that were implanted with osmotic pumps delivering either vehicle or KT-182. A. Analysis of average latency to fall from the rotarod measured across 7 trials showed that KT-182 did not affect motor coordination in WT mice but significantly rescued motor coordination in HdhQ200/200 mice. Statistical analysis: One-way ANOVA analysis (multiple comparisons using Tukey) indicated a 31%

reduction in latency to fall in HdhQ200/200 mice compared to WT mice and a 53% rescue of latency to fall in HdhQ200/200 mice when treated with KT-182. B. KT-182 treatment did not affect latency to fall in WT mice but C. enhanced latency to fall in HdhQ200/200 mice. Statistical analysis: Two-way ANOVA analysis with Bonferroni post-hoc analysis indicated significant rescue of motor coordination deficits in HdhQ200/200 by KT-182 compared to vehicle-treated HdhQ200/200 mice. D. Slow motor learning was comparable between HdhQ200/200 mice and WT littermates and not affected by treatment with KT-182. N = 6-7 mice per condition, error bars represent S.E.M. and * $p < 0.05$, ** $p < 0.01$.

Figure 5

Semi-chronic inhibition of ABHD6 did not affect spontaneous locomotion of wild-type and HdhQ200/200 mice at 10 months of age. Spontaneous locomotion (meters/hour) was measured in female wild type (WT) and HdhQ200/200 mice (10 months of age) that were implanted with osmotic pumps delivering either vehicle or KT-182 using PhenoTyper chambers. A. Distance traveled during the first hour of entering the PhenoTyper chamber indicates exploration of a novel environment and was unaffected by genotype or KT-182 treatment. Distance traveled measured during the B. dark phase (high activity, 12 hours) and C. light phase (low activity, 12 hours). Statistical analysis: One-way ANOVA analysis (multiple comparisons using Tukey) indicated a 41% reduction in spontaneous locomotion in HdhQ200/200 compared to WT measured during the dark phase but no difference between vehicle and KT-182. N = 6 mice per condition, error bars represent S.E.M. and * $p < 0.05$.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFigures.pdf](#)